Bibliographic Details
| Title: |
The utilization and safety of apixaban for therapeutic anticoagulation in heart transplant population requiring routine endomyocardial biopsies. |
| Authors: |
Lindauer, Kristen E.1 (AUTHOR), Ingemi, Amanda I.1 (AUTHOR) aiingemi@sentara.com, McMahon, Megan R.2 (AUTHOR), Lichvar, Alicia3 (AUTHOR), Baran, David A.4 (AUTHOR), Cameron, Chad1 (AUTHOR), Badiye, Amit5 (AUTHOR), Sawey, Edward J.5 (AUTHOR), Old, Wayne5 (AUTHOR), Yao, Andrew1 (AUTHOR), Yehya, Amin5 (AUTHOR), Herre, John M.5 (AUTHOR) |
| Source: |
Clinical Transplantation. Dec2022, Vol. 36 Issue 12, p1-4. 4p. |
| Subject Terms: |
*HEART transplantation, *HEART transplant recipients, *APIXABAN, *ORAL medication, *ANTICOAGULANTS, *KIDNEY transplantation, *CARDIAC amyloidosis |
| Abstract: |
Purpose: Routine endomyocardial (EM) biopsies pose a challenge in the management of heart transplant recipients requiring anticoagulation. Apixaban is a direct‐acting oral anticoagulant (DOAC) with a short half‐life allowing for brief interruptions of anticoagulation for procedures. The study objective was to determine the safety and efficacy of apixaban in heart transplant patients undergoing EM biopsies. Methods: This retrospective case series evaluated patients with a heart transplant from April 1, 2017 to July 30, 2020 who were treated with apixaban within 90 days post‐transplant. The primary outcome was the occurrence of a bleeding or thrombotic event. Results: A total of 12 patients with >100 biopsies were included. The median age was 54 years (IQR 37–59) with a mean weight of 91 ± 20 kg. There were no bleeding or thrombotic events. During therapy, patients underwent an average of eight biopsies. The median time from transplant to initiation of apixaban was 39.5 days (range 9–77). Therapy was maintained without any need for reversal for a median of 276 days (IQR 45–245). Conclusions: Apixaban is safe to use for anticoagulation of heart transplant recipients undergoing routine biopsies. Using apixaban allows for a short interruption of therapeutic anticoagulation to accommodate a biopsy without increased risk of bleeding. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Transplantation is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
